Zentalis Pharmaceuticals (ZNTL) presented an update on its azenosertib program at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, outlining clinical readout timing, dosing strategy and regulatory pathway for the WEE1 inhibitor in platinum-resistant ovarian cancer.
CEO Julie Eastland and CMO Ingmar Bruns discussed the azenosertib clinical portfolio alongside new commercial leadership, with Sarah Kelly joining as head of commercial activities. Analyst Mike Gold of Morgan Stanley moderated the session.
Azenosertib targets patients with high Cyclin E1 protein expression in platinum-resistant ovarian cancer, a population representing roughly 50% of that patient group — approximately 20,000 patients across the U.S., EU5, U.K. and Japan. Clinical data from the DENALI program (Parts 1B, 2A, 2B, 2C), MAMMOTH and ZN-c3-001 studies showed response rates consistently above 30%, with duration of response exceeding five months. Dosing spanned one to 13 prior lines of therapy across the trials.
The company selected a 400-milligram dose over 300 milligrams based on superior efficacy with broadly comparable safety and tolerability. The regimen uses a five-on, two-off schedule and has been tested across more than 1,000 patients.
The DENALI program features a seamless design with Parts 2A, 2B and 2C feeding an integrated analysis intended to support accelerated approval in the U.S. Part 2A compared 300mg versus 400mg and has completed enrollment. Part 2B expansion cohort enrollment is complete. Part 2C, added to reflect real-world treatment patterns including prior taxane exposure, is currently enrolling. Data readout from DENALI has been shifted to the first half of 2025.
Separately, the ASPENOVA trial is a 420-patient randomized controlled study with 1:1 randomization against investigator’s choice of single-agent chemotherapy — paclitaxel, pegylated liposomal doxorubicin, gemcitabine or topotecan — designed to support both accelerated and full global approval.
Beyond the lead indication, Zentalis reported a proof-of-concept study in second-line maintenance ovarian cancer combining azenosertib with bevacizumab, preclinical work in triple-negative breast cancer using antibody-drug conjugates and single-agent paclitaxel in patient-derived xenograft models, and early research in HPV-driven disease.
On the balance sheet, Zentalis reported $175 million in cash at the end of the second quarter of 2024 and raised an additional $92.6 million in August 2024, providing a combined cash runway into the first half of 2028, roughly a year beyond the expected DENALI data readout. Levered free cash flow over the trailing 12 months was negative $128 million, and the company posted a current ratio of 4.82.
Shares traded at $3.53, with a market capitalization of $334 million. The stock has returned 160% year-to-date despite a 12% decline over the prior week, and carries a beta of 1.86. Analyst price targets range from $4 to $10.
